Neurocrine Biosciences (NBIX) Stock Could Still Be A Bargain After A 61% Run

Neurocrine Biosciences stock has delivered a solid 60.9% return over the past 5 years, yet it still screens as undervalued on broader checks, which makes the current price level a live question for valuation driven investors. With fresh clinical progress in its pipeline and a high overall value score, Neurocrine Biosciences now sits in that zone where the recent share gains and the still supportive metrics need to be weighed carefully.

• Over the past 5 years, a 60.9% return suggests Neurocrine Biosciences has already rewarded patient holders. Any new position therefore needs to consider how much of that strength is already reflected in the price.
• The recent FDA acceptance of the investigational new drug application for a Phase 2 study of NBI-1117567 for Alzheimer's cognition can support sentiment around the pipeline. At the same time, trial and execution risk around that and other programs may limit how much value investors are willing to credit in advance.
• A high overall value score of 5 suggests the broader checks lean cheap rather than expensive for Neurocrine Biosciences at current levels.

The issue now is whether Neurocrine Biosciences stock still offers enough valuation appeal after its multi year gains to interest investors who are focused on price paid versus fundamentals.

Scan beyond Neurocrine Biosciences and compare its setup with a hand picked group of quality stocks that still screen as cheap using our 47 high quality undervalued stocks

Is Neurocrine Biosciences a Bargain on Earnings?

The P/E ratio is a useful cross check for Neurocrine Biosciences because it directly compares what you pay today with the earnings the business already generates. Neurocrine Biosciences currently trades on a P/E of about 22.4x, which is higher than the Biotechs industry average of 17.0x but below the peer group average of 59.9x. That places the stock in a middle ground where it is not the cheapest in the sector, yet far from the richest compared with closer peers.

The fair P/E ratio implied by broader checks sits around 25.0x, slightly above the current 22.4x. Despite the recent FDA acceptance of the Phase 2 study for NBI-1117567 influencing sentiment around the story, the market still prices Neurocrine Biosciences at a discount to this fair multiple. On this framework, the P/E suggests the stock offers some valuation cushion rather than pricing in an aggressive earnings outlook.

On the P/E multiple, Neurocrine Biosciences stock appears undervalued relative to the fair ratio implied by its fundamentals and risk profile.

See what the numbers say about this price — find out in our valuation breakdown.

The Neurocrine Biosciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the valuation puzzle around Neurocrine Biosciences leaves off by explaining which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price, and by setting these out on the company’s Community page. Each one assigns a fair value to a clear story about Neurocrine Biosciences' potential catalysts and risks, so you can track over time which version of events appears to be taking shape.

One of the top community narratives on Neurocrine Biosciences: 27% undervalued

"A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings…"

Read one of the top narratives on Neurocrine Biosciences

Do you think there's more to the story for Neurocrine Biosciences? Head over to our Community to see what others are saying!

The Bottom Line

Neurocrine Biosciences screens as undervalued on market multiples, which suggests the current P/E leaves room for upside if the business delivers on its existing earnings base and pipeline potential. The high value score aligns with that signal and indicates the broader checks lean supportive rather than stretched at today’s price. From here, the key debate is whether the pipeline, including newer programs like NBI-1117567, converts into durable earnings that justify any future re rating, or whether trial and execution risk keeps the stock on a cheaper multiple for longer.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com